Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Arjun Pandey, Iva Okaj, Hargun Kaur, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 17
Open Access | Times Cited: 86

Showing 26-50 of 86 citing articles:

SGLT inhibitors for improving Healthspan and lifespan
James H. O’Keefe, Robert Weidling, Evan L. O’Keefe, et al.
Progress in Cardiovascular Diseases (2023) Vol. 81, pp. 2-9
Open Access | Times Cited: 15
SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
Aritra Paul, Chadi Tabaja, Oussama M. Wazni
International Journal of Arrhythmia (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Rehma Siddiqui, Yoshitsugu Obi, Neville R. Dossabhoy, et al.
Current Hypertension Reports (2024) Vol. 26, Iss. 12, pp. 463-474
Open Access | Times Cited: 5
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 5
The potential anti-arrhythmic effect of SGLT2 inhibitors
Hong-Yi Duan, Héctor Barajas-Martínez, Charles Antzelevitch, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Clinical Update in Heart Failure with Preserved Ejection Fraction
Chayakrit Krittanawong, William Britt, Affan Rizwan, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 5, pp. 461-484
Closed Access | Times Cited: 5
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
Antonis A. Manolis, Theodora A. Manolis, Helen Melita, et al.
Trends in Cardiovascular Medicine (2022) Vol. 33, Iss. 7, pp. 418-428
Closed Access | Times Cited: 20
Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study
Arvid Engström, Viktor Wintzell, Mads Melbye, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 351-360
Open Access | Times Cited: 19
Autonomic Nervous System and Cardiac Metabolism
Praloy Chakraborty, Kassem Farhat, Sunny S. Po, et al.
JACC. Clinical electrophysiology (2023) Vol. 9, Iss. 7, pp. 1196-1206
Open Access | Times Cited: 12
Relationship between sodium‐glucose cotransporter 2 inhibitors and atrial fibrillation recurrence after pulmonary vein isolation in patients with type 2 diabetes and persistent atrial fibrillation
Dan Qi, Xiaonan Guan, Xiaoqing Liu, et al.
Journal of Cardiovascular Electrophysiology (2024) Vol. 35, Iss. 9, pp. 1799-1805
Closed Access | Times Cited: 4
Impact of Sodium‐Glucose Co‐Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post‐Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Naser Abdelhadi, Khaled Mohamed Ragab, Mohammed Elkholy, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Electrographic Flow Mapping Provides Prognosis for AF Ablation Outcomes Across Two Independent Prospective Patient Cohorts
Kent R. Nilsson, Amitesh Anerao, Melissa H. Kong, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 693-693
Open Access
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
Yongin Cho, Sung‐Hee Shin, Min-Ae Park, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0314454-e0314454
Open Access
The Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence and Long‐Term Clinical Outcomes in HFrEF Patients Undergoing Cryoballoon Ablation: A New Frontier Beyond Diabetes and Heart Failure
Elif Hande Özcan Çetin, Mehmet Serkan Çetin, Hasan Can Könte, et al.
Journal of Cardiovascular Electrophysiology (2025)
Closed Access
The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
Nakul Chandan, Vishnu Ashok, T. S. HWANG, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 3
Open Access
A Holistic Approach to Improving Outcomes in Atrial Fibrillation: The AF-CARE Pathway
Michael Griffin, Mark T Mills
British Journal of Hospital Medicine (2025) Vol. 86, Iss. 4, pp. 1-5
Closed Access
Predictors of Atrial Fibrillation Recurrence After Catheter Ablation: A State-of-the-Art Review
Roopeessh Vempati, Ayushi Garg, Maitri Shah, et al.
Hearts (2025) Vol. 6, Iss. 2, pp. 12-12
Open Access
Obesity as a risk factor for cardiac arrhythmias
Kiran Haresh Kumar Patel, Rohin K. Reddy, Arunashis Sau, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000308-e000308
Open Access | Times Cited: 16
SGLT2 inhibitors: an evidence-based update on cardiovascular implications
Imma Forzano, Scott Wilson, Angela Lombardi, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 9, pp. 839-847
Closed Access | Times Cited: 10
Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices
Carlos Minguito‐Carazo, Enrique Sánchez Muñoz, Moisés Rodríguez‐Mañero, et al.
Revista Española de Cardiología (English Edition) (2024) Vol. 77, Iss. 6, pp. 481-489
Closed Access | Times Cited: 3
Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions
Adriana Castello Costa Girardi, Juliano Z. Polidoro, Paulo C. Castro, et al.
AJP Cell Physiology (2024) Vol. 327, Iss. 3, pp. C525-C544
Closed Access | Times Cited: 3
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials
Dimitrios Sfairopoulos, Tong Liu, Nan Zhang, et al.
Heart Failure Reviews (2022) Vol. 28, Iss. 4, pp. 925-936
Open Access | Times Cited: 15
Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors
M. Donniacuo, Antonella De Angelis, Marialucia Telesca, et al.
Pharmacological Research (2022) Vol. 188, pp. 106591-106591
Open Access | Times Cited: 15
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
И Е Чазова, Н М Чихладзе, N. V. Blinova, et al.
Systemic Hypertension (2024) Vol. 21, Iss. 4, pp. 5-110
Open Access | Times Cited: 2

Scroll to top